USOR 17079 – FLEX Registry: Evaluate New Gene Expressions
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Available at Chicago Ridge, Orland Park
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Available at Chicago Ridge, Orland Park
A Phase III, Open-Label, Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Available at Chicago Ridge, Orland Park
A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
Available at Chicago Ridge, Orland Park
Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)
Available at Chicago Ridge, Orland Park
A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%.
Available at Chicago Ridge, Orland Park
STAR: SELECTED TRIALS AVAILABLE FOR ACCELERATED FOUR WEEK ROLLOUT
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Available at Chicago Ridge, Orland Park
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants with Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
Available at Chicago Ridge, Orland Park
If you are interested in learning more about our cancer research program, you can read frequently asked questions about clinical trials answered by the cancer research specialists at Affiliated Oncologists.
To find out more about a clinical trial listed here and if you are eligible for participation, you can call or request an appointment at the Affiliated Oncologists location where the trial is available, including Chicago Ridge and Orland Park.